LVs, with a packaging capacity of 8–10 kb, can accommodate therapeutic genes that surpass the limits of AAV, including ABCA4 (about 6.8 kb) and USH2A (about 15.6 kb), fitting for uses in Stargardt disease and Usher syndrome [64]. This evidence concerns the gene ABCA4 and Stargardt disease.